In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival

Схожие документы

• Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
  по: Brave, SR, и др.
  Опубликовано: (2011)
• A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
  по: Pacey, S, и др.
  Опубликовано: (2016)
• Regulation of VEGFR3 signaling in lymphatic endothelial cells
  по: Kevin G. Kuonqui, и др.
  Опубликовано: (2025-02-01)
• Trafficking dynamics of VEGFR1, VEGFR2, and NRP1 in human endothelial cells.
  по: Sarvenaz Sarabipour, и др.
  Опубликовано: (2024-02-01)
• Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.
  по: Smith, N, и др.
  Опубликовано: (2010)